UK markets open in 1 hour 1 minute
  • NIKKEI 225

    23,494.34
    -22.25 (-0.09%)
     
  • HANG SENG

    24,918.78
    +132.68 (+0.54%)
     
  • CRUDE OIL

    38.95
    -0.90 (-2.26%)
     
  • GOLD FUTURES

    1,899.00
    -6.20 (-0.33%)
     
  • DOW

    28,335.57
    -28.13 (-0.10%)
     
  • BTC-GBP

    10,052.43
    +34.00 (+0.34%)
     
  • CMC Crypto 200

    263.06
    +1.60 (+0.61%)
     
  • ^IXIC

    11,548.28
    +42.28 (+0.37%)
     
  • ^FTAS

    3,310.38
    +41.84 (+1.28%)
     

Global Molecular Diagnostics Partnering Terms and Agreements 2014-2020: Company A-Z, Headline Value, Stage of Development at Signing, Deal Component Type, Specific Therapy Target & Technology Type

Research and Markets
·4-min read

Dublin, Sept. 24, 2020 (GLOBE NEWSWIRE) -- The "Global Molecular Diagnostics Partnering Terms and Agreements 2014 to 2020" report has been added to ResearchAndMarkets.com's offering.

The Global Molecular Diagnostics Partnering Terms and Agreements 2014-2020 report provides a detailed understanding and analysis of how and why companies enter molecular diagnostics partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest Molecular Diagnostics agreements announced in the life sciences since 2014.

The report takes the reader through a comprehensive review Molecular Diagnostics deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Molecular Diagnostics partnering deals.

The report presents financial deal term values for Molecular Diagnostics deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.

The middle section of the report explores the leading dealmakers in the Molecular Diagnostics partnering field; both the leading deal values and most active Molecular Diagnostics dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.

One of the key highlights of the report is that over 7650 online deal records of actual Molecular Diagnostics deals, as disclosed by the deal parties, are included towards the end of the report in a directory format - by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.

In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

A comprehensive series of appendices is provided organized by Molecular Diagnostics partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

Report scope

Global Molecular Diagnostics Partnering Terms and Agreements includes:

  • Trends in Molecular Diagnostics dealmaking in the biopharma industry since 2014

  • Analysis of Molecular Diagnostics deal structure

  • Access to headline, upfront, milestone and royalty data

  • Case studies of real-life Molecular Diagnostics deals

  • Access to Molecular Diagnostics contract documents

  • Leading Molecular Diagnostics deals by value since 2014

  • Most active Molecular Diagnostics dealmakers since 2014

Available deals are listed by:

  • Company A-Z

  • Headline value

  • Stage of development at signing

  • Deal component type

  • Specific therapy target

  • Technology type

Key Topics Covered:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Molecular Diagnostics dealmaking
2.1. Introduction
2.2. Molecular Diagnostics partnering over the years
2.3. Most active Molecular Diagnostics dealmakers
2.4. Molecular Diagnostics partnering by deal type
2.5. Molecular Diagnostics partnering by therapy area
2.6. Deal terms for Molecular Diagnostics partnering
2.6.1 Molecular Diagnostics partnering headline values
2.6.2 Molecular Diagnostics deal upfront payments
2.6.3 Molecular Diagnostics deal milestone payments
2.6.4 Molecular Diagnostics royalty rates

Chapter 3 - Leading Molecular Diagnostics deals
3.1. Introduction
3.2. Top Molecular Diagnostics deals by value

Chapter 4 - Most active Molecular Diagnostics dealmakers
4.1. Introduction
4.2. Most active Molecular Diagnostics dealmakers
4.3. Most active Molecular Diagnostics partnering company profiles

Chapter 5 - Molecular Diagnostics contracts dealmaking directory
5.1. Introduction
5.2. Molecular Diagnostics contracts dealmaking directory

Chapter 6 - Molecular Diagnostics dealmaking by technology type

Chapter 7 - Partnering resource center
7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking

Appendices
Appendix 1 - Molecular Diagnostics deals by company A-Z
Appendix 2 - Molecular Diagnostics deals by stage of development
Discovery
Preclinical
Phase I
Phase II
Phase III
Regulatory
Marketed
Formulation
Appendix 3 - Molecular Diagnostics deals by deal type
Asset purchase
Assignment
Bigpharma outlicensing
Co-development
Collaborative R&D
Co-market
Co-promotion
CRADA
Cross-licensing
Development
Distribution
Equity purchase
Evaluation
Grant
Joint venture
Licensing
Litigation
Manufacturing
Marketing
Material transfer
Option
Promotion
Research
Settlement
Spin out
Sub-license
Supply
Technology transfer
Termination
Warranty
Appendix 4 - Molecular Diagnostics deals by therapy area
Appendix 5 -Deal type definitions

For more information about this report visit https://www.researchandmarkets.com/r/eh34fs

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900